Merus reports revenues of $49.0 million for fiscal 2015

Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] is pleased to report its financial results for fiscal year ending September 30, 2015.

Corporate Highlights

Revenues for fiscal 2015 were $49.0 million. Had the Company recorded Sintrom, Salagen and Estraderm on a gross basis, (which is explained below and better reflects in-market net sales) revenue for fiscal 2015 would have been $66.1 million, generating an adjusted EBITDA margin of 49%.

Earnings before interest, taxes, depreciation and amortization ("EBITDA") was $29.9 million and adjusted EBITDA which adds back non-cash share based compensation expense, foreign exchange, investment expenses, derivative gains and losses and acquisition costs was $32.6 million.

"Over the last year we successfully executed on our business priorities – strengthening our team, building strategic partnerships, optimizing current products, securing two additional established medicines, and advancing on several promising acquisition opportunities. Our scalable platform is well-positioned to take on new products, and we are committed to delivering long-term growth for our shareholders."

"Our underlying business, based on IMS data from pharmacy purchases, is performing as expected. Sintrom demand was stable year-over-year despite the launch of several new oral anticoagulants (NOACs) over the past few years. Emselex demand declined at 5% year-over-year due to intense competition in the overactive bladder market. However, our focused demand-creation strategies in select markets for Emselex have made an impact. As an example, net sales in the UK have increased by more than 60% during the last twelve months," commented Barry Fishman, Chief Executive Officer.

Merus incurred a net loss of $0.2 million in fiscal 2015, compared to a net loss of $8.1 million for the prior fiscal year. The Company ended fiscal 2015 with $41.0 million in cash and $23.0 million in net debt, resulting in a leverage ratio to fiscal 2015 adjusted EBITDA of 0.7.

Emselex Sales and German Pricing Update

Revenues for Emselex in fiscal 2015 were $27.4 million, compared to $20.7 million in the prior fiscal year. Increased revenues for Emselex were driven primarily by the December 2014 expiration of a legacy marketing agreement in Germany and an increase in sales in the UK due to our value creation efforts.

As previously communicated, in July 2014, the German Federal Joint Committee (GB-A) initiated a process to review the establishment of a new "jumbo class" for overactive bladder products. Merus has been notified that Emselex will be included in this new class, and was informed today that the proposed maximum reimbursement price will be set at approximately 40% of our current weighed average net selling prices. Germany represented approximately 40% of fiscal 2015 Emselex net sales. There is a one month comment period for the marketing authorization holders, and barring any change, the new regime is expected to take effect in the March/April 2016 timeframe. The proposed price level and expected implementation timing are in-line with Company expectations.

Other Product Sales

Revenues for Sintrom in fiscal 2015 were $15.5 million, compared to $1.0 million in the prior fiscal year. The increase is related to a full year of sales compared with less than one month in the prior year. During the current year, Sintrom revenues were recorded on a net basis, after deducting cost of goods and commercial expenses, subject to a transition period whereby Novartis continues to provide certain functions for a fee until the marketing authorizations are transferred. During this period Merus acts as an agent and revenues are recorded on a net basis. Had the Company recorded Sintrom on a gross basis throughout the fiscal year, revenues and cost of goods would have been higher by $16.2 million.

During September 2015, Merus received its marketing authorization for Spain, the major market for Sintrom, and switched to recording sales on a gross basis. At the same time, the Company acquired and sold the local stocking inventory (approximately 2 months of inventory) to its commercial partner.

Merus acquired Salagen and Estraderm in May 2015. Revenues from Salagen during the year ended September 30, 2015 were $2.1 million. Similar to Sintrom, had the Company recorded Salagen on a gross basis, revenues and cost of goods would have been higher by $0.5 million. Revenues from Estraderm during the year ended September 30, 2015 were $0.7 million. Had the Company recorded Estraderm on a gross basis, revenues and cost of goods would have been higher by $0.5 million.

Vancocin revenues were $3.3 million in fiscal 2015, compared to $4.4 million for the prior fiscal year. The decrease is primarily due to the entry of a second generic vancomycin, which started to gain traction during the third quarter of fiscal 2014.

Selling, General & Administrative (SG&A) Expenses

SG&A expenses were $11.3 million for the fiscal year 2015, compared to $9.6 million in fiscal 2014. Selling expenses decreased in fiscal 2015 when compared to fiscal 2014, driven by right-sizing our contract sales force in Canada and one-time strategic investment made in fiscal 2014 to reclassify Emselex within the prescribing guidelines in the UK for products treating overactive bladder, which drove incremental physician prescribing. Excluding the impact of non-cash share based compensation, G&A expenses increased primarily due to legal costs (including the Factive arbitration), increased headcount, and due diligence related to potential product acquisitions.

Future Guidance

The Company anticipates fiscal 2016 adjusted EBITDA, without consideration of new acquisitions, to be in the $30 million range.